Schering Claritin Patent Ruling Unlikely To Affect Clarinex Exclusivity
Executive Summary
The outcome of Schering-Plough's Claritin patent litigation is unlikely to have a significant effect on the exclusivity for the successor drug Clarinex
You may also be interested in...
Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case
Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case
Claritin Patent Case May Define Value Of Metabolite Patents
Innovators will still have a viable method for protecting metabolites if the Claritin patent ruling is upheld, a federal appellate court judge said April 8
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: